[HTML][HTML] Hepatitis C virus: A critical approach to who really needs treatment

E Kouroumalis, A Voumvouraki - World Journal of Hepatology, 2022 - ncbi.nlm.nih.gov
Introduction of effective drugs in the treatment of hepatitis C virus (HCV) infection has
prompted the World Health Organization to declare a global eradication target by 2030 …

Care facilitation advances movement along the hepatitis C care continuum for persons with human immunodeficiency virus, hepatitis C, and substance use: a …

LR Metsch, DJ Feaster, LK Gooden… - Open forum …, 2021 - academic.oup.com
Background Direct-acting antivirals can cure hepatitis C virus (HCV). Persons with HCV/HIV
and living with substance use are disadvantaged in benefiting from advances in HCV …

Pangenotypic and Genotype-Specific Antivirals in the treatment of HCV Genotype 4 infected patients with HCV monoinfection and HIV/HCV coinfection

D Zarębska-Michaluk, J Jaroszewicz… - Journal of Clinical …, 2022 - mdpi.com
The introduction of the direct-acting antivirals (DAA) has substantially improved the
effectiveness of the therapy in patients with chronic hepatitis C. We aimed to compare the …

Successful treatment of hepatitis C virus infection in patients on anti‐epileptics or mood stabilizers using pharmacokinetic enhancers

J Yin, L Hill, M Mansour, S Collier… - British Journal of …, 2023 - Wiley Online Library
Co‐administration of hepatitis C virus (HCV) direct‐acting antivirals (DAAs) with anti‐
epileptics or mood stabilizers with cytochrome P450 (CYP) and/or drug transport‐inducing …

[HTML][HTML] The treatment choices and outcome of hepatocellular carcinoma in hemophilic patients with human immunodeficiency virus/hepatitis C virus (HIV/HCV) …

M Takatsuki, K Natsuda, M Hidaka… - Journal of …, 2021 - ncbi.nlm.nih.gov
Background Human immunodeficiency virus (HIV) and hepatitis C virus (HCV) coinfection
through unheated blood product for hemophilia caused in early 1980s has been significantly …

[HTML][HTML] Primer reporte en Perú sobre terapia con antivirales de acción directa para hepatitis C crónica en pacientes VIH-positivos

JA Collins Camones, ER Chamorro Chirinos… - Revista de …, 2022 - scielo.org.pe
Resumen COLLINS CAMONES, Jaime Antonio; CHAMORRO CHIRINOS, Elena Rocío y
LOYOLA SALVATIERRA, Fiorella Vanessa. Primer reporte en Perú sobre terapia con …

[图书][B] A Bioinformatic Pipeline for the Detection of Drug Resistant Mutations for Bacterial and Viral Pathogens

E Pennington - 2023 - search.proquest.com
The development of drug resistant mutations in bacterial and viral pathogens is an emerging
threat to global public health. The rampant propagation of drug resistant pathogens has …

索磷布韦/维帕他韦单用或联合利巴韦林治疗3B 型HCV/HIV 感染者的效果及安全性.

刘立, 常丽仙, 陈智勇, 李俊义… - Journal of Clinical …, 2024 - search.ebscohost.com
目的观察索磷布韦/维帕他韦单用或联合利巴韦林方案对我国基因3B 型HCV/HIV
感染者的治疗效果和安全性. 方法选取2017 年1 月—2020 年12 月于昆明市第三人民医院就诊 …

Efficacy, Tolerability, and Compliance of Direct Acting Antivirals in Patients with HIV and Hepatitis C Coinfection: A Real-Life Experience

S Mishra, S Taneja, A De, N Verma… - AIDS Research and …, 2023 - liebertpub.com
Effective management of HIV and hepatitis C virus (HCV) coinfection warrants special
emphasis on interactions between direct acting antivirals (DAAs) and antiretroviral therapy …

[图书][B] Methodological Advances to Address Measurement Error and Model Misspecification in HIV Research

RP Kyle - 2023 - search.proquest.com
Advances in antiretroviral therapy have led to drastic improvements in survival among
people living with HIV. However, as life expectancies have increased, so too has the …